Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Reference69 articles.
1. D’Angelo S, Secondulfo M, De Cristofano R, et al. Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit. Future Oncol. 2013;9(4):485–91.
2. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): hepatobiliary cancers (version 2.2016). 2016. http://www.nccn.org/ . Accessed 16 Jan 2017.
4. Bayer HealthCare Pharmaceuticals Inc. Nexavar (sorafenib) tablets, oral: US prescribing information. 2013. http://labeling.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf . Accessed 16 Jan 2017
5. European Medicines Agency. Nexavar (sorafenib): EU summary of product characteristics. 2016. http://www.ema.europa.eu/ . Accessed 7 Feb 2017.
Cited by
246 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献